Litcius/Paper detail

Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial

Nasser K. Altorki, Timothy E. McGraw, Alain Borczuk, Ashish Saxena, Jeffrey L. Port, Brendon M. Stiles, Benjamin E. Lee, Nicholas J Sanfilippo, Ronald Scheff, Bradley B. Pua, James F. Gruden, Paul J. Christos, Cathy Spinelli, Joyce Gakuria, Manik Uppal, Bhavneet Binder, Olivier Elemento, Karla V. Ballman, Silvia C. Formenti

2021The Lancet Oncology330 citationsDOI

Topics & Concepts

DurvalumabMedicineRadiation therapyOncologyLung cancerStage (stratigraphy)Internal medicineClinical trialCancerNeoadjuvant therapyImmunotherapyNivolumabBreast cancerBiologyPaleontologyCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentRadiomics and Machine Learning in Medical Imaging
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial | Litcius